News

Immunomic Therapeutics Announces the Appointment of Frances Harrison as Senior Vice President, Regulatory Affairs   September 06, 2022 09:00 AM Eastern Daylight Time   ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”),

Immunomic Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ITI-3000 pDNA Vaccine for the Treatment of Merkel Cell Carcinoma -Top line data expected in second half of

https://biobuzz.io/brian-stamper-appointed-vice-president-cell-therapy-operations-at-immunomic-therapeutics/

June 07, 2022 10:24 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein) -mediated nucleic

Immunomic Therapeutics highlighted in Washington Business Journal as a life sciences leader in Maryland’s Montgomery County: The Immunology Capital Next to the Nation’s Capital. Click here to read more: http://ow.ly/NQrc50IVzkT

Claire Rosean, Senior Scientist discusses ITI-3000, First-In-Human Trial for Merkel Cell Carcinoma and the preclinical data presented at AACR. Click below to watch the full interview: https://www.oncologytube.com/video/40935/claire-rosean-phd-immunomix-uw-aacr22-mcc-iti-3000-first-in-human-trial?channelName=AACR 

April 14, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today that

Both DNA Cancer Vaccines Studied Were Derived from Immunomic’s UNITE™ Platform Phase 1 Study of MCPyV-LT Vaccine in Merkel Cell Carcinoma to Begin in Q2 April 08, 2022 01:15 PM Eastern

March 31, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today that

Read the latest Washington Business Journal article highlighting Immunomic Therapeutics by clicking the link below: https://www.bizjournals.com/washington/news/2022/03/17/immunomic-therapeutics-expanding-hiring-pre-ipo.html

February 11, 2022 08:00 AM Eastern Standard Time   ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today

February 07, 2022 01:48 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein) -mediated nucleic